Inclisiran—Safety and Effectiveness of Small Interfering RNA in Inhibition of PCSK-9
Sign Up to like & getrecommendations! Published in 2023 at "Pharmaceutics"
DOI: 10.3390/pharmaceutics15020323
Abstract: Dyslipidemia is listed among important cardiovascular disease risk factors. Treating lipid disorders is difficult, and achieving desirable levels of LDL-cholesterol (LDL-C) is essential in both the secondary and primary prevention of cardiovascular disease. For many… read more here.
Keywords: small interfering; safety effectiveness; interfering rna; inclisiran safety ... See more keywords